JNJ-26854165 (Serdemetan)

Catalog No.S1172

JNJ-26854165 (Serdemetan) Chemical Structure

Molecular Weight(MW): 328.41

JNJ-26854165 (Serdemetan) acts as a HDM2 ubiquitin ligase antagonist and also induces early apoptosis in p53 wild-type cells, inhibits cellular proliferation followed by delayed apoptosis in the absence of functional p53. Phase 1.

Size Price Stock Quantity  
In DMSO USD 140 In stock
USD 110 In stock
USD 370 In stock
USD 970 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

6 Customer Reviews

  • Sci Rep 2014 4, 4663. JNJ-26854165 (Serdemetan) purchased from Selleck.

    Sci Rep 2014 4, 4663. JNJ-26854165 (Serdemetan) purchased from Selleck.

  • Sci Rep 2014 4, 4663. JNJ-26854165 (Serdemetan) purchased from Selleck.

    Mol Pharmacol 2014 85(3), 408-19. JNJ-26854165 (Serdemetan) purchased from Selleck.

  • J Nat Med 2013 10.1007/s11418-014-0825-0. JNJ-26854165 (Serdemetan) purchased from Selleck.

    Curr Protoc Chem Biol 2013 5(3), 195-212. JNJ-26854165 (Serdemetan) purchased from Selleck.

Purity & Quality Control

Choose Selective p53 Inhibitors

Biological Activity

Description JNJ-26854165 (Serdemetan) acts as a HDM2 ubiquitin ligase antagonist and also induces early apoptosis in p53 wild-type cells, inhibits cellular proliferation followed by delayed apoptosis in the absence of functional p53. Phase 1.
Targets
p53 [1]
(Cell-free assay)
HDM2 [1]
(Cell-free assay)
Mdm2 [2]
(Cell-free assay)
In vitro

JNJ 26854165 is a novel tryptamine derivative which activates p53 and acts as a HDM2 ubiquitin ligase antagonist. JNJ 26854165 inhibits cell growth and induces apoptosis in leukemia cell lines with IC50 values of 0.24, 0.33, 0.32 and 0.44 μM at 72 hours for OCI-AML-3, MOLM-13, NALM-6 and REH cells, respectively. In addition, JNJ 26854165 accelerates proteasome-mediated degradation of p21 and antagonizes the transcriptional induction of p21 by p53. It also induces S-phase delay and upregulates E2F1 expression in p53 mutant cells, resulting in preferential apoptosis of S-phase cells. [1] JNJ 26854165 is an oral Mdm2 inhibitor which can inhibit the interaction of Mdm2-p53 complex with the proteasome and increase p53 levels by binding to RING domain of Mdm2. [2] A recent study shows that JNJ 26854165 inhibits clonogenic survival in four human cancer cell lines: H460, A549, p53-WT-HCT116, and p53-null-HCT116. [3]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
KU-19-19 cell M3TUbGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVn4cZduUW6qaXLpeIlwdiCxZjDoeY1idiCNVT2xPU0yQSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTBwOUOyN|Yh|ryP MlywV2FPT0WU
H4 cell MV\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{jxR2lvcGmkaYTpc44hd2ZiaIXtZY4hUDRiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD1zLkC2O|A4KM7:TR?= MnzSV2FPT0WU
KGN cell NXvMUIFST3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVfk[XhVUW6qaXLpeIlwdiCxZjDoeY1idiCNR16gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2xMlYzODVizszN M17SfXNCVkeHUh?=
786-0 cell MlLMS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MYPJcohq[mm2aX;uJI9nKGi3bXHuJFc5Pi1yIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;MT63Nlk5QSEQvF2= MonWV2FPT0WU
769-P cell MULHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NF\6c4xKdmirYnn0bY9vKG:oIHj1cYFvKDd4OT3QJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9NU45OjJ{NDFOwG0> MnzYV2FPT0WU
K5 cell MlnMS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NU\ndXU2UW6qaXLpeIlwdiCxZjDoeY1idiCNNTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuNFE3OjRizszN NGj3SotUSU6JRWK=
MLMA cell MUfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? Mkf0TY5pcWKrdHnvckBw\iCqdX3hckBMV1OFLUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2yMlA{OjF5IN88US=> NX\XeXN6W0GQR1XS
MLMA cell NX7yTXRrT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M{jZVWlvcGmkaYTpc44hd2ZiaIXtZY4hVUyPQTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuNlg4ODNizszN NWj6RZJOW0GQR1XS
EW-7 cell NV;URYNxT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M2W2UGlvcGmkaYTpc44hd2ZiaIXtZY4hTVdvNzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUKuN|I3QTVizszN NGDnfXBUSU6JRWK=
SW1088 cell MVzHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NHH1Nm1KdmirYnn0bY9vKG:oIHj1cYFvKFOZMUC4PEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVIvQDB4NUGg{txO M2rSc3NCVkeHUh?=
MC-IXC cell MoO0S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NYf4bJY4UW6qaXLpeIlwdiCxZjDoeY1idiCPQz3JXGMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0zNjh5N{myJO69VQ>? NH;LS4lUSU6JRWK=
NCI-H2052 cell NUO3TIFDT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NIOwVFlKdmirYnn0bY9vKG:oIHj1cYFvKE6FST3INlA2OiClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTNwMEixOVch|ryP MnjsV2FPT0WU
IGR-1 cell NYi0UZptT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MnTITY5pcWKrdHnvckBw\iCqdX3hckBKT1JvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuNVIxOjhizszN NWTpNpF7W0GQR1XS
DSH1 cell Mor5S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NUTZZWtYUW6qaXLpeIlwdiCxZjDoeY1idiCGU1ixJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{4zPDJ7NjFOwG0> NGLFb|dUSU6JRWK=
PA-1 cell NInncmFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2rtVGlvcGmkaYTpc44hd2ZiaIXtZY4hWEFvMTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuN|AxPToQvF2= NFHVO49USU6JRWK=
SK-MEL-3 cell MW\Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M13RNGlvcGmkaYTpc44hd2ZiaIXtZY4hW0tvTVXMMVMh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF0{NjNzMkC3JO69VQ>? NXqwNZFLW0GQR1XS
SW900 cell MVrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{X6UWlvcGmkaYTpc44hd2ZiaIXtZY4hW1d7MECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME2zMlQ5OjV3IN88US=> MXrTRW5ITVJ?
CAKI-1 cell MoPPS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFjkWFRKdmirYnn0bY9vKG:oIHj1cYFvKEODS1mtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvPTJ5M{ig{txO MoO4V2FPT0WU
ES1 cell MUnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{LoZmlvcGmkaYTpc44hd2ZiaIXtZY4hTVNzIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Mz61Nlg6PyEQvF2= Mnz2V2FPT0WU
SK-N-DZ cell NUWweXdtT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MonUTY5pcWKrdHnvckBw\iCqdX3hckBUUy2QLVTaJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{43OjV7NTFOwG0> MVfTRW5ITVJ?
RH-1 cell NEHJdGlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NWS1R3JLUW6qaXLpeIlwdiCxZjDoeY1idiCUSD2xJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{43QDR4MzFOwG0> MnfoV2FPT0WU
ES8 cell NVzo[mQ4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NIDMfW1KdmirYnn0bY9vKG:oIHj1cYFvKEWVODDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuOlk4ODJizszN NEj4fppUSU6JRWK=
NEC8 cell NYfJdYV4T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NXjIcolmUW6qaXLpeIlwdiCxZjDoeY1idiCQRVO4JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9N{44Pjl6MjFOwG0> M3fGeXNCVkeHUh?=
LNCaP-Clone-FGC cell NU\DVXFnT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MYTJcohq[mm2aX;uJI9nKGi3bXHuJGxPS2GSLVPsc45mNU[JQzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUOuPFM2OzZizszN Ml;WV2FPT0WU
HCE-4 cell M3jWbWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NYK5bWdbUW6qaXLpeIlwdiCxZjDoeY1idiCKQ1WtOEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVMvQThyNzFOwG0> NEPUcXFUSU6JRWK=
U-118-MG cell MXfHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NXzGXVBOUW6qaXLpeIlwdiCxZjDoeY1idiCXLUGxPE1OTyClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTRwMEGwOlYh|ryP MXfTRW5ITVJ?
GI-ME-N cell M3O1fmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 Mmi3TY5pcWKrdHnvckBw\iCqdX3hckBIUS2PRT3OJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE4xQDd7NjFOwG0> MX7TRW5ITVJ?
LB1047-RCC cell MknVS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NEDwTXpKdmirYnn0bY9vKG:oIHj1cYFvKEyEMUC0O{1TS0NiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD12LkG2NVQ{KM7:TR?= MUnTRW5ITVJ?
HT-1080 cell M1;oXGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NH\U[WxKdmirYnn0bY9vKG:oIHj1cYFvKEiWLUGwPFAh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01NjF7OUKxJO69VQ>? MkPmV2FPT0WU
NB69 cell M1m4dWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NF;IdI9KdmirYnn0bY9vKG:oIHj1cYFvKE6ENkmgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20MlM2ODR5IN88US=> M3jEb3NCVkeHUh?=
NCI-H1693 cell MWLHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M1LRNmlvcGmkaYTpc44hd2ZiaIXtZY4hVkOLLVixOlk{KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC52NEi5OUDPxE1? M2i4OHNCVkeHUh?=
HSC-3 cell MVjHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MXvJcohq[mm2aX;uJI9nKGi3bXHuJGhUSy1|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND60PVk{OyEQvF2= MXjTRW5ITVJ?
MDA-MB-231 cell NFfwXplIem:5dHigbY5pcWKrdHnvckBie3OjeR?= M4D3c2lvcGmkaYTpc44hd2ZiaIXtZY4hVUSDLV3CMVI{OSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTRwNUW4PVkh|ryP NH\PSINUSU6JRWK=
HOS cell NVnaXmZmT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3rpWmlvcGmkaYTpc44hd2ZiaIXtZY4hUE:VIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;ND63PFY{KM7:TR?= NGDrNVJUSU6JRWK=
BT-549 cell NUjnVHhbT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NUniNIVYUW6qaXLpeIlwdiCxZjDoeY1idiCEVD21OFkh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF01Njd6OEeg{txO NUT1OI9sW0GQR1XS
NB17 cell NV3ydZFLT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NV24RpZbUW6qaXLpeIlwdiCxZjDoeY1idiCQQkG3JINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OE44QDl5NjFOwG0> MX7TRW5ITVJ?
5637 cell MmXES5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NIfRVWVKdmirYnn0bY9vKG:oIHj1cYFvKDV4M{egZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME20Mlc6PjV{IN88US=> M4DUUnNCVkeHUh?=
OVCAR-8 cell NXm3RoNET3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= NVLrfGp6UW6qaXLpeIlwdiCxZjDoeY1idiCRVlPBVk05KGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PC57MkSzOkDPxE1? M3HiVXNCVkeHUh?=
G-402 cell NUPLO25MT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MmPVTY5pcWKrdHnvckBw\iCqdX3hckBINTRyMjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUSuPVMxOzVizszN MYrTRW5ITVJ?
BB30-HNC cell MnnQS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmK4TY5pcWKrdHnvckBw\iCqdX3hckBDSjNyLVjOR{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvODd{MUig{txO MVfTRW5ITVJ?
HCC1806 cell NGDHT21Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= MV7Jcohq[mm2aX;uJI9nKGi3bXHuJGhESzF6ME[gZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlA5OzN7IN88US=> MYjTRW5ITVJ?
COLO-800 cell MmLkS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MWPJcohq[mm2aX;uJI9nKGi3bXHuJGNQVE9vOECwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU4yOjZ2IN88US=> NUnib29sW0GQR1XS
FADU cell M{HEUGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NVP5dZNNUW6qaXLpeIlwdiCxZjDoeY1idiCIQVTVJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU4{PjV3NzFOwG0> NXrkbm03W0GQR1XS
NCI-H1651 cell NW\BWZBvT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MorRTY5pcWKrdHnvckBw\iCqdX3hckBPS0lvSEG2OVEh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF02NjN7NEC5JO69VQ>? MlfNV2FPT0WU
AGS cell NH\0PG1Iem:5dHigbY5pcWKrdHnvckBie3OjeR?= M2PtT2lvcGmkaYTpc44hd2ZiaIXtZY4hSUeVIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT60O|cyOSEQvF2= MmDUV2FPT0WU
CHP-212 cell NH25RYdIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MUTJcohq[mm2aX;uJI9nKGi3bXHuJGNJWC1{MUKgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21MlM6PDB7IN88US=> NVHWRYp5W0GQR1XS
YAPC cell NIDrcHFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkHzTY5pcWKrdHnvckBw\iCqdX3hckB[SVCFIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT60O|cyOSEQvF2= NWr4eXJnW0GQR1XS
GOTO cell Mom2S5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M2PD[GlvcGmkaYTpc44hd2ZiaIXtZY4hT0:WTzDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuOFk2PzZizszN NV\yS4dOW0GQR1XS
KYSE-510 cell MV7Hdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MVXJcohq[mm2aX;uJI9nKGi3bXHuJGt[W0VvNUGwJINmdGxiZ4Lve5RpKGmwIHGgZ4VtdCC4aXHibYxqfHliYYPzZZktKEmFNUC9OU42OTFizszN MVHTRW5ITVJ?
NCI-H2342 cell MkfHS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVThZph2UW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFI{PDJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13LkWzNlc5KM7:TR?= Mn7zV2FPT0WU
BFTC-905 cell MUXHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NX\0OW5WUW6qaXLpeIlwdiCxZjDoeY1idiCERmTDMVkxPSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwNkK4N|Uh|ryP MmfIV2FPT0WU
EW-16 cell MnLuS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? MmPnTY5pcWKrdHnvckBw\iCqdX3hckBGXy1zNjDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPUWuO|IxQTNizszN M3rTb3NCVkeHUh?=
SK-MEL-30 cell M4XtZmdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NEnmc2VKdmirYnn0bY9vKG:oIHj1cYFvKFONLV3FUE0{OCClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTVwN{S1OFMh|ryP M12wOnNCVkeHUh?=
HLE cell MWrHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? M{DxZ2lvcGmkaYTpc44hd2ZiaIXtZY4hUEyHIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT63O|Q5QSEQvF2= MWjTRW5ITVJ?
T98G cell NYH2fYI1T3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MmnCTY5pcWKrdHnvckBw\iCqdX3hckBVQTiJIHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;NT63PVY{PSEQvF2= NF3lZlFUSU6JRWK=
HUTU-80 cell MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NUDlenhmUW6qaXLpeIlwdiCxZjDoeY1idiCKVWTVMVgxKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:PS56NEKyPEDPxE1? MYTTRW5ITVJ?
NOS-1 cell MljwS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NVTPc|k5UW6qaXLpeIlwdiCxZjDoeY1idiCQT2OtNUBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvQTR5Nk[g{txO MYLTRW5ITVJ?
SW780 cell NUDuR4cyT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= M3e0fGlvcGmkaYTpc44hd2ZiaIXtZY4hW1d5OECgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME21Mlk3QTR7IN88US=> MXrTRW5ITVJ?
KYSE-180 cell M1vvPGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 MlnGTY5pcWKrdHnvckBw\iCqdX3hckBMYVOHLUG4NEBk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVUvQTd4NUSg{txO MXTTRW5ITVJ?
MDA-MB-361 cell M3L6fWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NGnDcopKdmirYnn0bY9vKG:oIHj1cYFvKE2GQT3NRk0{PjFiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD13Lkm4OlQ4KM7:TR?= MlHmV2FPT0WU
SNU-C2B cell MoXaS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? NFW0cHlKdmirYnn0bY9vKG:oIHj1cYFvKFOQVT3DNmIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03NjBzMUO4JO69VQ>? NWn5b3hiW0GQR1XS
NCI-H661 cell M4TSTWdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXi3Z4lxUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFY3OSClZXzsJIdzd3e2aDDpckBiKGOnbHygeoli[mmuaYT5JIF{e2G7LDDJR|UxRTZwME[5OEDPxE1? NGjWVmpUSU6JRWK=
OE33 cell NYjWWJZNT3Kxd4ToJIlvcGmkaYTpc44h[XO|YYm= MlG2TY5pcWKrdHnvckBw\iCqdX3hckBQTTN|IHPlcIwh\3Kxd4ToJIlvKGFiY3XscEB3cWGkaXzpeJkh[XO|YYmsJGlEPTB;Nj6xOFM5QSEQvF2= NYXRWpg1W0GQR1XS
TYK-nu cell NIThVWFIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWLJcohq[mm2aX;uJI9nKGi3bXHuJHR[Uy2wdTDj[YxtKGe{b4f0bEBqdiCjIHPlcIwhfmmjYnnsbZR6KGG|c3H5MEBKSzVyPU[uNlE5PjNizszN NFvoTGVUSU6JRWK=
COLO-792 cell MlyyS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? M3jNZWlvcGmkaYTpc44hd2ZiaIXtZY4hS0:OTz23PVIh[2WubDDndo94fGhiaX6gZUBk\WyuII\pZYJqdGm2eTDhd5NigSxiSVO1NF03NjJ3MkG5JO69VQ>? NH:yVmVUSU6JRWK=
HEL cell MXnHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? MnXTTY5pcWKrdHnvckBw\iCqdX3hckBJTUxiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD14LkK2O|Yh|ryP MnfyV2FPT0WU
D-566MG cell MVPHdo94fGhiaX7obYJqfGmxbjDhd5NigQ>? NV;OOYhFUW6qaXLpeIlwdiCxZjDoeY1idiCGLUW2Om1IKGOnbHyg[5Jwf3SqIHnuJIEh[2WubDD2bYFjcWyrdImgZZN{[XluIFnDOVA:Pi5|M{S5NUDPxE1? NIrSb4VUSU6JRWK=
U031 cell NHrUZ5FIem:5dHigbY5pcWKrdHnvckBie3OjeR?= NFvtO29KdmirYnn0bY9vKG:oIHj1cYFvKFVyM{GgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlQyQDF4IN88US=> NULwfXMzW0GQR1XS
COR-L23 cell NIHzUGhIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MWXJcohq[mm2aX;uJI9nKGi3bXHuJGNQWi2OMkOgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlQ{OzR4IN88US=> MonSV2FPT0WU
NCI-H2452 cell M1vVXGdzd3e2aDDpcohq[mm2aX;uJIF{e2G7 NXnF[m1kUW6qaXLpeIlwdiCxZjDoeY1idiCQQ1mtTFI1PTJiY3XscEBoem:5dHigbY4h[SClZXzsJJZq[WKrbHn0fUBie3OjeTygTWM2OD14LkWyNlgyKM7:TR?= M13sUXNCVkeHUh?=
BB65-RCC cell NGq2VVlIem:5dHigbY5pcWKrdHnvckBie3OjeR?= MkDaTY5pcWKrdHnvckBw\iCqdX3hckBDSjZ3LWLDR{Bk\WyuIHfyc5d1cCCrbjDhJINmdGxidnnhZoltcXS7IHHzd4F6NCCLQ{WwQVYvPjR3OTFOwG0> NYLrfZFkW0GQR1XS
CAL-33 cell MlvjS5Jwf3SqIHnubIljcXSrb36gZZN{[Xl? Mn\vTY5pcWKrdHnvckBw\iCqdX3hckBESUxvM{OgZ4VtdCCpcn;3eIghcW5iYTDj[YxtKH[rYXLpcIl1gSCjc4PhfUwhUUN3ME22MlY2PjZ3IN88US=> NV7OXpR7W0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo JNJ 26854165 leads to significant differences in EFS distribution in 17 of the 36 (47%) evaluable solid tumor xenografts and in 5 of 7 (71%) of the evaluable ALL xenografts using a dose of 20 mg/kg administered via oral gavage daily for 5 days, repeated for 6 weeks. [4]

Protocol

Cell Research:[1]
+ Expand
  • Cell lines: OCI-AML-3, MOLM-13, NB4 and U937 cells
  • Concentrations: 0-10 μM
  • Incubation Time: 72 hours
  • Method: Cell lines are maintained in RPMI 1640 medium containing 10% heat-inactivated fetal calf serum (FCS). OCI-AML-3, MOLM-13, NB4 and U937 cells are derived from acute myelogenous leukemia (AML) patients, K562 from a chronic myelogenous leukemia (CML) patient in blast crisis, and NALM-6, REH, P12-ICHIK
    (Only for Reference)
Animal Research:[4]
+ Expand
  • Animal Models: CB17SC scid-/- female mice.
  • Formulation: JNJ-26854165 is dissolved in DMSO and then diluted in water.
  • Dosages: ≤20 mg/kg
  • Administration: Administered via p.o.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 66 mg/mL (200.96 mM)
Ethanol 2 mg/mL (6.08 mM)
Water Insoluble
In vivo Add solvents individually and in order:
1% DMSO+30% polyethylene glycol+1% Tween 80
30 mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 328.41
Formula

C21H20N4

CAS No. 881202-45-5
Storage powder
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00676910 Completed Neoplasms Johnson & Johnson Pharmaceutical Research & Development, L.L.C. November 2006 Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

p53 Signaling Pathway Map

Related p53 Products

Tags: buy JNJ-26854165 (Serdemetan) | JNJ-26854165 (Serdemetan) supplier | purchase JNJ-26854165 (Serdemetan) | JNJ-26854165 (Serdemetan) cost | JNJ-26854165 (Serdemetan) manufacturer | order JNJ-26854165 (Serdemetan) | JNJ-26854165 (Serdemetan) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID